Evaluation of ocular safety: Tirapazamine plus cisplatin in patients with metastatic melanomas

Anti-Cancer Drugs

Volumn 9, Issue 6, 1998, Pages 515-524

  Prager, Thomas C ^a,c   Kellaway, Judianne ^a   Zou, Yali ^a   Urso, Richard G ^a   McIntyre, Susan ^b   Bedikian, Agop Y ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Hermann Eye Center   (United States)

Author keywords

Cisplatin; Metastatic melanoma; Ocular toxicity; Tirapazamine

Indexed keywords

CISPLATIN; TIRAPAZAMINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLOR VISION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG SCREENING; ELECTROOCULOGRAM; EYE TOXICITY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA HEMORRHAGE; RETINA NERVE CELL; VISION TEST; VISUAL ACUITY;

EID: 0031816803     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199807000-00001     Document Type: Article

References (25)

1. Brown JM. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 1993; 67: 1163-70.
2. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Biophys 1986; 12: 1239-42.
3. Lartigau E, Guichard M. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours. Br J Cancer 1996; 73: 1480-5.
4. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993; 53: 4633-6.
5. Wilding G, Carusa R, Lawrence TS, Ostchega Y, Ballintin EJ, Young RC, Ozols. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol 1985; 3: 1683-9.
6. Pippitt CH, Hyman BM, Homesley HD, Jacob VW. Cisplatin associated cortical blindness. Gynecol Oncol 1981; 12: 253-5.
7. Miller DF, Bay JW, Lederman RJ, Purvis JD, Rogers LR, Tomsak RL. Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas. Ophthalmology 1985; 92: 402-6
8. Khawly JA, Rubin P, Petros W, Peters WP, Jaffe GJ. Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. Ophthalmology 1996; 103: 87-95.
9. Aylward JM. Hydroxychloroquine and chloroquine: assessing the risk of retinal toxicity. J Am Optom Ass 1993; 64: 787-97.
10. Kato I, Watanabe J, Nakamura T, Harada K, Hasegawa T, Kanayama R. Mapping of brainstem lesions by the combined use of tests of visually-induced eye movements. Brain 1990; 113: 921-35.
11. Pall H, Blake DR, Winyard P, et al. Ocular toxicity of desferrioxamine - an example of copper promoted auto-oxidative damage? Br J Ophthalmol 1989; 73: 42-7.
12. De Laey JJ, De Rouck A, Priem H, Vanhoorne M. Ophthalmological aspects of chronic CS2 intoxication. Int Ophthalmol 1980; 3: 51-6.
13. Weiss JN, Ochs AL, Ahedi S, Selhorst JB. Retinopathy after tilorone hydrochloride. Am J Ophthal 1980; 90: 846-53.
14. Marmor MF. Clinical electrophysiology of the retinal pigment epithelium. Documenta Ophthalmologica 1991; 76: 301-13.
15. Kellner Um Kleine-Hartlage P, Foerster MH. Cone dystrophies: clinical and electrophysiological findings. German J Ophthalmol 1992; 1: 105-9
16. Bailey IL, Lovie JE. New design principles for visual acuity letter charts. Am J Optom Physiol Optics 1976; 53: 740-5.
17. Ferris FL III, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982; 94: 91-6.
18. Holladay JT, Prager TC. Mean visual acuity. Am J Ophthalmol 1991; 111: 372-4.
19. Prager T, Urso R, Holladay J, Stewart R. Glare testing in cataract patients: instrument evaluation and identification of sources of methodological error. J Cataract Refractive Surg 1989; 15: 149-57.
20. Vingrys AJ, King-Smith PE. A quantitative scoring technique for panel tests of color vision. Invest Ophthal Vis Sci 1988; 29: 50-63.
21. Atchison DA, Bowman KJ, Vingrys AJ. Quantitative scoring methods for D15 panel tests in the diagnosis of congenital color vision deficiencies. Optom Vision Sci 1991; 68: 41-8.
22. Marmor MF, Zrenner E. Standard for clinical electro-oculography. International Society for Clinical Electrophysiology of Vision. Arch Ophthal 1993; 111: 601-4.
23. Zonneveldt A, van Lith G. The electrooculogram and its interindividual and intraindividual variability. Ophthalmologica 1980; 181: 165-9.
24. Alanko HI. Clinical electro-oculography. Acta Ophthalmol 1984; 61: 139-48.
25. Krogh E. Normal values in clinical electrooculography. V. Variability within and between eyes. Acta Ophthalmol 1977; 55: 986-93.